Russian generics producers start paying compensations to Novo Nordisk

Leading Russian drugmakers PSK Pharma and Promomed, which produce the analogues of Ozempic - a drug for the treatment of diabetes, based on semaglutide - have made their first payments to its original producer –  Denmark’s Novo Nordisk (NOV: N), creating a precedent of the possibility of similar payments to original drugmakers in Russia, reports The Pharma Letter’s local correspondent.

The amount of the compensations is not disclosed, however, according to some Russian lawyers, compensation in such cases is usually 0.5% of the actual revenue of manufacturers that produce such generics.

Novo Nordisk told Russian media that it “did not participate in any negotiations regarding semaglutide in Russia and did not receive license fees.” According to Russian laws, such payments for companies from «unfriendly» countries are sent to special accounts of type “O.”